Terril Brothers Inc. Has $6.61 Million Stake in Globus Medical, Inc. (NYSE:GMED)

Terril Brothers Inc. decreased its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 0.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 79,950 shares of the medical device company’s stock after selling 325 shares during the period. Globus Medical accounts for approximately 2.0% of Terril Brothers Inc.’s portfolio, making the stock its 14th biggest position. Terril Brothers Inc.’s holdings in Globus Medical were worth $6,613,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Quarry LP raised its position in Globus Medical by 698.4% during the third quarter. Quarry LP now owns 495 shares of the medical device company’s stock worth $35,000 after acquiring an additional 433 shares in the last quarter. Farther Finance Advisors LLC raised its position in Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after acquiring an additional 385 shares in the last quarter. UMB Bank n.a. raised its position in Globus Medical by 60.2% during the fourth quarter. UMB Bank n.a. now owns 548 shares of the medical device company’s stock worth $45,000 after acquiring an additional 206 shares in the last quarter. V Square Quantitative Management LLC raised its position in Globus Medical by 52.0% during the fourth quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company’s stock worth $48,000 after acquiring an additional 197 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its position in Globus Medical by 24.7% during the fourth quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company’s stock worth $55,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GMED shares. Stifel Nicolaus upped their price target on shares of Globus Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a research report on Friday, February 21st. Canaccord Genuity Group upped their price target on shares of Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $83.00 to $100.00 in a research report on Monday, December 2nd. Finally, Piper Sandler increased their price objective on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $97.82.

Globus Medical Stock Performance

NYSE:GMED opened at $80.34 on Friday. Globus Medical, Inc. has a 52 week low of $49.33 and a 52 week high of $94.93. The firm has a market cap of $10.94 billion, a price-to-earnings ratio of 107.12, a P/E/G ratio of 1.61 and a beta of 1.19. The firm’s 50-day simple moving average is $86.46 and its 200 day simple moving average is $79.30.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The business had revenue of $657.29 million for the quarter, compared to analyst estimates of $646.19 million. Sell-side analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current year.

Insider Buying and Selling

In other Globus Medical news, SVP Kelly Huller sold 2,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $87.00, for a total transaction of $217,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The disclosure for this sale can be found here. 18.54% of the stock is owned by insiders.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.